CytoSPAR


CytoSPAR is at the forefront of transforming healthcare diagnostics for complicated Urinary Tract Infections (cUTI) with its innovative BLAST technology. This next-generation Antibiotic Susceptibility Test enables healthcare professionals to swiftly identify the most effective antibiotic treatments, enhancing patient care and outcomes. The system provides rapid, accurate results directly from urine samples in just 5 hours, significantly reducing traditional testing times and integrating seamlessly into laboratory workflows. CytoSPAR is committed to innovation in combating antibiotic resistance and improving healthcare diagnostics.

Industries

biotechnology

CytoSPAR

Easton, Pennsylvania, United States, North America


Products

Rapid bacteria-labeling antibiotic susceptibility testing system (research use)

A research-use diagnostic system that analyzes bacterial responses to antibiotics directly from urine samples to produce susceptibility profiles and MIC information in approximately 5 hours without a bacterial growth phase.

Expertise Areas

  • Phenotypic antibiotic susceptibility testing
  • Direct-from-sample diagnostic assays
  • UTI and complicated-UTI diagnostics
  • Antimicrobial resistance testing
  • Show More (2)

Key Technologies

  • Bacterial labeling techniques
  • Real-time bacterial response monitoring
  • Phenotypic antibiotic susceptibility testing
  • Direct-from-urine sample testing
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.